A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (NCT03768063)
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.
Who can join: Review the eligibility criteria below.
Location: University of Colorado Cancer Center — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (80 Sites)
Showing the first 25 of 80 sites.
- University of Colorado Cancer Center — Aurora, Colorado
- Yale University School Of Medicine — Trumbull, Connecticut
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Carolina BioOncology Institute, PLCC — Huntersville, North Carolina
- St. Luke's Cancer Care Associates — Bethlehem, Pennsylvania
- University of Texas Health Sciences Center in San Antonio — San Antonio, Texas
- St Vincent'S Hospital — Darlinghurst, New South Wales
- UZ Leuven — Leuven, Flemish Brabant
- Institut Jules Bordet — Brussels,
- UZ Brussel — Brussels,
- Hospital das Clinicas - UFRGS — Porto Alegre, Rio Grande do Sul
- Multiprofile Hospital for Active Treatment Central Onco Hospital OOD — Plovdiv,
- Pontificia Universidad Catolica de Chile — Santiago,
- Masaryk?v onkologický ústav — Brno,
- Rigshospitalet — København Ø,
- CHU Angers — Angers, Pays de la Loire Region
- Centre Antoine Lacassagne — Nice, Provence-Alpes-Côte d'Azur Region
- Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez — Lille,
- hopital de la Timone — Marseille,
- Institut Gustave Roussy — Villejuif, Île-de-France Region
- Universitätsklinikum Ulm — Ulm, Baden-Wurttemberg
- Krankenhaus Barmherzige Bruder Regensburg — Regensburg, Bavaria
- Universitätsklinikum Schleswig-Holstein;Campus Lübeck — Lübeck, Schleswig-Holstein
- Kliniken Essen-Mitte — Essen,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cancer
- Ovarian Tissue Cryopreservation in Children — Rochester, Minnesota
- Ex Onc SLED: A Study Utilizing A Weighted Sled for Horizontal Resistance Training — Pittsburgh, Pennsylvania
- An Internet-based Program to Help Cancer Survivors Manage Pain — Fort Smith, Arkansas
- Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors — Toronto, Ontario
- Researching the Effect of Aerobic Exercise on Cancer — Los Angeles, California
Explore by condition: All Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.